MacroGenics Inc. (MGNX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

MacroGenics Inc. (MGNX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

3.21

0.17 (5.59%)

At close: Jan 15, 2025, 3:59 PM

3.19

-0.47%

After-hours Jan 15, 2025, 04:00 PM EST

undefined% (undefined)

Bid	3.08
Market Cap	201.16M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.57
PE Ratio (ttm)	-2.04
Forward PE	n/a
Analyst	Hold

Ask	3.22
Volume	609,631
Avg. Volume (20D)	562,108
Open	3.10
Previous Close	3.04
Day's Range	3.04 - 3.22
52-Week Range	2.95 - 21.88
Beta	undefined

About MGNX

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 10, 2013

Employees 339

Stock Exchange NASDAQ

Ticker Symbol MGNX

Website https://www.macrogenics.com

Analyst Forecast

According to 10 analyst ratings, the average rating for MGNX stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 56.01% from the latest price.

Buy 20.00%

Hold 80.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

MacroGenics Inc. is scheduled to release its earnings on Mar 6, 2025, during market hours.
Analysts project revenue of $30.93M, reflecting a 188.53% YoY growth and earnings per share of -0.66, making a -12.00% decrease YoY.

Why Price Moved

2 months ago · Source

+1.89%

MacroGenics shares are trading higher after the co... Unlock content with Pro Subscription

4 months ago · Source

+6.15%

MacroGenics shares are trading higher after the company announced it is set to present Phase 2 results from its TAMARACK trial on innovative cancer treatment at ESMO 2024.

News

2 months ago · zacks.com

Here's What Key Metrics Tell Us About MacroGenics (MGNX) Q3 Earnings

The headline numbers for MacroGenics (MGNX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street ...

2 months ago · zacks.com

MacroGenics (MGNX) Beats Q3 Earnings and Revenue Estimates

MacroGenics (MGNX) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.17 per share. This compares to loss of $0.52 per share a year ago.

2 months ago · seekingalpha.com

MacroGenics, Inc. (MGNX) Q2 2024 Earnings Call Transcript

MacroGenics, Inc. (NASDAQ:MGNX ) Q2 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants James Karrels - Senior Vice President, Chief Financial Officer and Secretary Scott Ko...

2 months ago · businesswire.com

MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA®

ROCKVILLE, Md. & DEERFIELD, Ill.--(BUSINESS WIRE)--MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibo...